Target Name: MIR3187
NCBI ID: G100422854
Other Name(s): microRNA 3187 | MicroRNA 3187 | hsa-mir-3187 | mir-3187 | hsa-miR-3187-5p | hsa-miR-3187-3p

MIR3187: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent and often severe pain can have a significant impact on an individual's quality of life, leading to functional limitations, disability, and even depression. In addition, chronic pain can also have significant economic costs, including healthcare expenses and lost productivity.

MIR3187 is a potential drug target and biomarker that has been identified as a potential therapeutic approach for the treatment of chronic pain. In this article, we will discuss the background of MIR3187, its potential mechanisms of action, and its potential as a drug target and biomarker for the treatment of chronic pain.

Background

MIR3187 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of chronic pain. MIR3187 is expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues, and has been shown to play a role in the regulation of pain signaling.

Potential Mechanisms of Action

MIR3187 has been shown to play a role in the regulation of pain signaling by modulating the activity of pain-related genes. Specifically, MIR3187 has been shown to inhibit the activity of nociceitin, a potent pain-sensitizer, by binding to its nuclear receptor, TRPV1. This interaction between MIR3187 and TRPV1 has been shown to play a role in the regulation of pain sensitivity and the modulation of pain perception.

In addition to its role in modulating pain sensitivity, MIR3187 has also been shown to play a role in the regulation of pain modulation by modulating the activity of pain-related signaling pathways. Specifically, MIR3187 has been shown to inhibit the activity of the protein kinase ALCATAMIDE, which is involved in the regulation of pain signaling pathway. This interaction between MIR3187 and ALCATAMIDE has been shown to play a role in the regulation of pain sensitivity and the modulation of pain perception.

Potential as a Drug Target

MIR3187 has been shown to be a potential drug target for the treatment of chronic pain due to its role in the regulation of pain signaling. By inhibiting the activity of nociceitin and ALCATAMIDE, MIR3187 has been shown to have potential therapeutic benefits for the treatment of chronic pain.

In addition to its potential therapeutic benefits, MIR3187 also has the potential to serve as a biomarker for the diagnosis and monitoring of chronic pain. Specifically, MIR3187 has been shown to be expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues, making it a potential biomarker for the diagnosis and monitoring of chronic pain.

Potential as a Biomarker

MIR3187 has also been shown to have potential as a biomarker for the diagnosis and monitoring of chronic pain. The expression of MIR3187 in various tissues and cells, including brain, spinal cord, and peripheral tissues, makes it a potential biomarker for the diagnosis and monitoring of chronic pain.

In addition to its potential as a drug target, MIR3187 has also been shown to have potential as a biomarker for the diagnosis and monitoring of chronic pain. The expression of MIR3187 in various tissues and cells, including brain, spinal cord, and peripheral tissues, makes it a potential biomarker for the diagnosis and monitoring of chronic pain.

Conclusion

MIR3187 is a small non-coding RNA molecule that has been shown to play a role in the regulation of pain signaling by modulating the activity of pain-related genes and signaling pathways. In addition to its potential therapeutic benefits as a drug target for the treatment of chronic pain, MIR3187 also has the potential to serve as a biomarker for the diagnosis and monitoring of chronic pain. Further research is needed to fully understand the potential of MIR3187 as a drug target and biomarker for the treatment of chronic pain.

Protein Name: MicroRNA 3187

More Common Targets

MIR3188 | MIR3189 | MIR3190 | MIR3191 | MIR3192 | MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672